CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Multicenter Single-arm Study Evaluating the Safety and Efficacy of Everolimus as a First-line Treatment in Newly-diagnosed Patients With Advanced GI Neuroendocrine Tumors.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01648465
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:35.951956+00:00
Published At: 2019-09-03T00:00:00+00:00
Record Updated At: 2019-09-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Gastrointestinal Tumors", "Pancreatic Tumors", "Gastrointestinal Neuroendocrine Tumors", "Pancreatic Neuroendocrine Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-09-03"
protocolSection.identificationModule.nctId: "NCT01648465"
protocolSection.identificationModule.officialTitle: "Phase II Multicenter Single-arm Study Evaluating the Safety and Efficacy of Everolimus as a First-line Treatment in Newly-diagnosed Patients With Advanced GI Neuroendocrine Tumors."
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.